Troponin Screening and Major Cardiovascular Adverse Events During Immune Checkpoint Inhibitor Therapy - Quiz - MDSpire

Assessment of Troponin Levels and Significant Cardiovascular Events in Patients Undergoing Immune Checkpoint Inhibitor Treatment

  • By

  • Imen Hamdi

  • Nathan El Bèze

  • Soledad Henriquez

  • Marie-Liesse Joulia

  • Raphaël Colle

  • Delphine Loirat

  • Nicolas Girard

  • Agnès Lillo Le Louet

  • Christophe Caussin

  • Mariana Mirabel

  • July 21, 2026

Share

Original Source(s)

Troponin Screening and Major Cardiovascular Adverse Events During Immune Checkpoint Inhibitor Therapy

  • by Imen Hamdi, Nathan El Bèze, Soledad Henriquez, Marie-Liesse Joulia, Raphaël Colle, Delphine Loirat, Nicolas Girard, Agnès Lillo Le Louet, Christophe Caussin, Mariana Mirabel

  • July 21, 2026

Related Content

Retraction Note: Atovaquone inhibits colorectal cancer metastasis by regulating PDGFRβ/NF-κB signaling pathway

Treatment patterns and survival outcomes in elderly patients with intrahepatic cholangiocarcinoma: NCDB analysis

Expression and prognostic significance of INSM1 compared with traditional neuroendocrine markers in mixed urothelial and small-cell carcinoma of the renal pelvis